Materiały źródłowe

• #1 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Gaucher disease (GD) is a rare lysosomal storage disorder resulting from a deficiency of the lysosomal enzyme glucocerebrosidase caused by biallelic variants in the GBA1 gene. […] However, many patients with GD experience a lengthy diagnostic odyssey, which can negatively affect their access to care and clinical outcomes. […] This heterogeneity, combined with the molecular complexity of the GBA1 locus, low disease prevalence, and limited knowledge of GD among providers serves as a barrier to early diagnosis of GD. […] Due to the heterogenous nature of the disorder, relatively low prevalence, variation of presentation, and low provider familiarity, patients may experience lengthy diagnostic delays as well as extraneous testing and procedures. […] Earlier diagnosis is essential for improving patient outcomes.

• #2 Gaucher Disease Diagnosis and Management | VPRIV® (velaglucerase alfa) for injection

  https://www.vpriv.com/diagnosis

  The importance of early diagnosis of type 1 Gaucher disease cannot be understated; as a rare disease, GD1 can often go undiagnosed for longer than it should, and may be manageable with appropriate treatment. […] Patients with GD1 can experience diagnostic delays of up to 10 years; reasons for this can include a lack of awareness of GD1 due to its rarity and the fact that common symptoms of GD1 can mimic other, better-known conditions and lead to misdiagnoses. […] If you or your loved one is concerned about type 1 Gaucher disease, speak to your doctor and request a test. A simple test may be readily available, and your doctor can request this on your behalf to help confirm or rule out a GD1 diagnosis. […] Sometimes referred to as a dried blood spot test, this is a simple blood test that measures the levels of the enzyme, glucocerebrosidase. Low levels of this enzyme may indicate a need for genetic testing which would then confirm a diagnosis of GD1. […] Genetic testing helps to identify the specific genetic mutations that result in type 1 Gaucher disease and confirm a diagnosis.

• #3 Diagnosis of Gaucher disease

  https://pro.campus.sanofi/uk/gaucher/articles/diagnosis-of-gaucher-disease

  Early diagnosis is key. The early diagnosis and treatment of Gaucher disease are essential to prevent or reverse severe disease complications. However, when Gaucher is missed, a patient can remain untreated for up to 10 years. […] Haematologists play a pivotal role in diagnosis. In a survey of 136 Gaucher patients in the US, Australia and New Zealand: 86% were seen by a haematologist-oncologist in pursuit of a diagnosis in the US. […] In Australia and New Zealand, 73% of patients were seen by a haematologist-oncologist to obtain a diagnosis. However, a survey of over 400 haematology-oncologists in the US, Australia and New Zealand revealed that: 80% do not consider Gaucher disease in their differential diagnosis. […] Simple and effective diagnostic algorithms, such as the Cappellini protocol, make it easier to identify patients with suspected Gaucher disease.

• #4 Gaucher Disease Testing | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/testing/

  Physicians diagnose Gaucher disease (pronounced go-SHAY) with a standard blood test called a beta-glucosidase leukocyte (BGL) test available through major laboratories, i.e. Counsyl, Labcorp or Quest Diagnostics, as well as a hospital or doctors office. […] Doctors use a standard blood test called a beta-glucosidase leukocyte (BGL) test to check enzyme activity and diagnose Gaucher disease. […] Fortunately, bone marrow testing is not necessary to diagnose Gaucher disease. In fact, physicians can diagnose Gaucher disease with an enzyme test available at a hospital or your doctors office. […] An enzyme test called a beta-glucosidase leukocyte (BGL) test is the main tool that physicians use to diagnose Gaucher disease. This is because all patients with Gaucher disease will have low enzyme activity levels.

• #5 Gaucher Disease Diagnosis & Treatment | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/

  Testing for Gaucher disease (pronounced go-SHAY) is easy and involves a standard blood test called a beta-glucosidase leukocyte (BGL) test. […] Early diagnosis is critical for proactive Gaucher disease treatment, which helps minimize any permanent damage to the body. […] If you experience symptoms or if Gaucher disease runs in your family, it is important to get tested. Testing for Gaucher disease involves a standard blood test available at a hospital or doctors office. […] Physicians rely primarily on the BGL test for enzyme activity, also using genetic testing to identify specific mutations associated with Gaucher disease. […] A BGL test for enzyme activity will almost certainly show if you have Gaucher disease. All patients with Gaucher disease have low glucocerebrosidase (GCase) enzyme activity, which is why their bodies cannot break down glucocerebroside (a fatty chemical).

• #6 Gaucher Disease – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1269/

  Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal-lethal disorder to an asymptomatic type. […] The diagnosis of GD relies on demonstration of deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells, or by the identification of biallelic pathogenic variants in GBA1 on molecular genetic testing. […] The diagnosis of GD is established in a proband by the finding of 0%-15% of normal glucocerebrosidase enzyme activity in peripheral blood leukocytes (or other nucleated cells), or by the identification of biallelic pathogenic (or likely pathogenic) variants in GBA1 on molecular genetic testing. […] Molecular testing approaches can include single-gene testing or use of a multigene panel. […] Single-gene testing. Sequence analysis of GBA1 is performed first to detect missense, nonsense, and splice site variants and small intragenic deletions/insertions. […] A multigene panel that includes GBA1 and other genes of interest may also be considered to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.

• #7 Gaucher Disease Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/944157-workup

  Diagnosis can be confirmed through measurement of glucocerebrosidase activity in peripheral blood leukocytes. A finding of less than 15% of mean normal activity is diagnostic. […] Molecular diagnosis can be helpful, especially in Ashkenazi patients, in whom 6 GBA1 mutations (ie, N370S, c.84insG, L444P, IVS2+1ga, V394L, and R496H) account for around 90% of disease alleles. However, these variants only account for 50-75% in other ethnicities, and therefore sequencing of the exons of GBA1 is necessary in order to accurately establish the genotype. […] A CBC count with a platelet count and differential should be performed to assess the degree of cytopenia. […] Minor elevations of liver enzyme levels are common, even in patients who are mildly affected with Gaucher disease; however, the presence of jaundice or impaired hepatocellular synthetic function merits a full hepatic evaluation.

• #8 Clinical Roundtable Monograph: Disease State Awareness in Gaucher Disease: A Q&A Expert Roundtable Discussion – Hematology & Oncology

  https://www.hematologyandoncology.net/supplements/clinical-roundtable-monograph-disease-state-awareness-in-gaucher-disease-a-qa-expert-roundtable-discussion/

  Gaucher disease results from biallelic mutations in the glucocerebrosidase gene (GBA), which is assigned to a gene-dense region of chromosome 1q. Molecular analysis of the GBA1 gene is complex, as this gene is linked with an actively transcribed, highly homologous pseudogene that also harbors several mutations. However, only mutations in the active gene lead to Gaucher disease. […] The gold standard for the diagnosis of Gaucher disease is demonstration of low acid-β-glucosidase activity in peripheral blood leukocytes. (Measurement of acid-β-glucosidase activity can also be performed on cultured fibroblasts, which may be useful for prenatal diagnosis, but typically peripheral blood leukocytes are used for this test.) Compared to a healthy person, glucocerebrosidase activity is reduced 70–90% in a typical adult patient with Gaucher disease and more than 90% in children with more severe forms of the disease.

• #9 Gaucher Disease Diagnosis & Treatment | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/

  Testing for Gaucher disease (pronounced go-SHAY) is easy and involves a standard blood test called a beta-glucosidase leukocyte (BGL) test. […] Early diagnosis is critical for proactive Gaucher disease treatment, which helps minimize any permanent damage to the body. […] If you experience symptoms or if Gaucher disease runs in your family, it is important to get tested. Testing for Gaucher disease involves a standard blood test available at a hospital or doctors office. […] Physicians rely primarily on the BGL test for enzyme activity, also using genetic testing to identify specific mutations associated with Gaucher disease. […] A BGL test for enzyme activity will almost certainly show if you have Gaucher disease. All patients with Gaucher disease have low glucocerebrosidase (GCase) enzyme activity, which is why their bodies cannot break down glucocerebroside (a fatty chemical).

• #10 Gaucher Disease Testing | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/testing/

  A beta-glucosidase leukocyte (BGL) test will almost certainly show whether or not a person has Gaucher disease since all patients with the disease have low enzyme activity. […] For carrier testing, a targeted mutation test will identify roughly 89 percent of carriers. Gene sequencing can identify over 99 percent of Gaucher disease carriers. […] You should get tested if you experience symptoms of Gaucher disease, or if it runs in your family. […] A bone marrow test is not required to diagnose Gaucher disease. However, some doctors end up diagnosing Gaucher disease with this test while trying to rule out other blood disorders.

• #11 Gaucher Disease – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1269/

  Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal-lethal disorder to an asymptomatic type. […] The diagnosis of GD relies on demonstration of deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells, or by the identification of biallelic pathogenic variants in GBA1 on molecular genetic testing. […] The diagnosis of GD is established in a proband by the finding of 0%-15% of normal glucocerebrosidase enzyme activity in peripheral blood leukocytes (or other nucleated cells), or by the identification of biallelic pathogenic (or likely pathogenic) variants in GBA1 on molecular genetic testing. […] Molecular testing approaches can include single-gene testing or use of a multigene panel. […] Single-gene testing. Sequence analysis of GBA1 is performed first to detect missense, nonsense, and splice site variants and small intragenic deletions/insertions. […] A multigene panel that includes GBA1 and other genes of interest may also be considered to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.

• #12 Gaucher Disease Diagnosis & Treatment | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/

  Rarely, BGL test results can be inconclusive, in which case genetic testing can usually help clarify whether you have Gaucher disease. […] Genetic testing shows whether a person has the specific mutations associated with Gaucher disease. […] Physicians perform this test using a blood or saliva sample. […] Genetic testing can also detect who is a carrier of Gaucher disease. Carriers do not have the disease, but they may pass the gene to their children.

• #13 Gaucher Disease – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1269/

  Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal-lethal disorder to an asymptomatic type. […] The diagnosis of GD relies on demonstration of deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells, or by the identification of biallelic pathogenic variants in GBA1 on molecular genetic testing. […] The diagnosis of GD is established in a proband by the finding of 0%-15% of normal glucocerebrosidase enzyme activity in peripheral blood leukocytes (or other nucleated cells), or by the identification of biallelic pathogenic (or likely pathogenic) variants in GBA1 on molecular genetic testing. […] Molecular testing approaches can include single-gene testing or use of a multigene panel. […] Single-gene testing. Sequence analysis of GBA1 is performed first to detect missense, nonsense, and splice site variants and small intragenic deletions/insertions. […] A multigene panel that includes GBA1 and other genes of interest may also be considered to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.

• #14 Gaucher Disease – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1269/

  Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal-lethal disorder to an asymptomatic type. […] The diagnosis of GD relies on demonstration of deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells, or by the identification of biallelic pathogenic variants in GBA1 on molecular genetic testing. […] The diagnosis of GD is established in a proband by the finding of 0%-15% of normal glucocerebrosidase enzyme activity in peripheral blood leukocytes (or other nucleated cells), or by the identification of biallelic pathogenic (or likely pathogenic) variants in GBA1 on molecular genetic testing. […] Molecular testing approaches can include single-gene testing or use of a multigene panel. […] Single-gene testing. Sequence analysis of GBA1 is performed first to detect missense, nonsense, and splice site variants and small intragenic deletions/insertions. […] A multigene panel that includes GBA1 and other genes of interest may also be considered to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype.

• #15 Gaucher Disease Diagnosis & Treatment | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/

  Rarely, BGL test results can be inconclusive, in which case genetic testing can usually help clarify whether you have Gaucher disease. […] Genetic testing shows whether a person has the specific mutations associated with Gaucher disease. […] Physicians perform this test using a blood or saliva sample. […] Genetic testing can also detect who is a carrier of Gaucher disease. Carriers do not have the disease, but they may pass the gene to their children.

• #16 Diagnosis and Testing Overview | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/diagnosis-testing

  The -glucosidase enzyme assay measures the levels of the enzyme glucocerebrosidase.5 A GD diagnosis is confirmed by establishing glucocerebrosidase enzyme activity in mononuclear cells, leukocytes, or cultured fibroblasts. These are obtained by either a skin biopsy or dried blood spot test.68 Low levels of this enzyme, less than 15% of mean normal activity, indicate a diagnosis of GD.6,9 Enzyme activity, however, does not predict disease severity.1,6 […] Genetic testing requires either a blood or saliva sample, used to extract the patients DNA.10 Genetic sequencing can then be used to detect specific mutations in the GBA1 gene that result in GD.11,12 […] Due to the rare nature and heterogeneous presentation of GD1, patients often consult several different specialists before reaching the correct diagnosis.16,17 Although clinical presentation of variable severity occurs in childhood for the majority of patients, diagnosis is often delayed 1015 years until patients are in adulthood.15,17 Patients are often misdiagnosed, which can lead to disease complications, persistence of untreated symptoms, emotional distress, and frustration and depression at the lack of an explanation for their symptoms.6

• #17 Gaucher Disease Testing | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/testing/

  A beta-glucosidase leukocyte (BGL) test will almost certainly show whether or not a person has Gaucher disease since all patients with the disease have low enzyme activity. […] For carrier testing, a targeted mutation test will identify roughly 89 percent of carriers. Gene sequencing can identify over 99 percent of Gaucher disease carriers. […] You should get tested if you experience symptoms of Gaucher disease, or if it runs in your family. […] A bone marrow test is not required to diagnose Gaucher disease. However, some doctors end up diagnosing Gaucher disease with this test while trying to rule out other blood disorders.

• #18 Gaucher’s disease: Causes, treatment, and outlook

  https://www.medicalnewstoday.com/articles/263370

  If signs and symptoms suggest that Gauchers disease may be present, or if there is a family history, the doctor will refer the individual to a genetic specialist. […] Blood tests can identify low levels of glucocerebrosidase. […] Genetic testing looks for the four most common genetic mutations, N370S, L444P, 84gg and IVS2[+1], and some less common ones. […] This test is not completely reliable because the whole range genetic mutations that may be linked with Gauchers disease are not yet known. […] Genetic testing for these four mutations is between 90 and 95 percent accurate in diagnosing Gauchers disease in the Ashkenazi Jewish population, and 50 percent to 60 percent accurate in the general population. […] Genetic testing combined with the enzyme test helps diagnose Gauchers disease accurately.

• #19 Diagnosis And Treatment Options For Gaucher Disease – Klarity Health Library

  https://my.klarity.health/diagnosis-and-treatment-options-for-gaucher-disease/

  Genetic testing is used to identify mutations in the GBA gene, which encodes the glucocerebrosidase enzyme: DNA analysis: Testing for common GBA1 gene mutations can confirm the diagnosis. The most commonly mutated genes are N370S and 84GG. Genetic testing helps in identifying carriers and providing genetic counselling for families. […] Imaging studies help assess the extent of organ involvement and bone disease: Magnetic Resonance Imaging (MRI): It can identify the liver and spleen enlargement and the degree of bone marrow infiltration. […] Diagnosing Gaucher disease involves a combination of clinical evaluation, enzyme activity tests, genetic testing, and imaging studies to confirm the presence of the disorder and differentiate it from other conditions.

• #20 Gaucher Disease Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/944157-workup

  Angiotensin-converting enzyme levels typically are elevated, as are total acid phosphatase and ferritin levels. […] In recent years levels of glucosylsphingosine, a downstream metabolic product of glucosylceramide, have been shown to be a useful disease biomarker, as it correlates with disease severity and with response to therapy. […] Bone marrow aspiration should not be the initial diagnostic test because the blood enzyme test is sensitive, specific, and much less invasive; in fact, such biopsies rarely are indicated. […] Liver biopsy occasionally is performed to assess unexplained hepatomegaly. However, it should be avoided in most patients when the diagnosis is suspected because a specific diagnostic test is available. […] In Gaucher disease, classic glycolipid-laden macrophages are found in bone marrow aspirate or in liver biopsy samples. […] Histologic evaluation of biopsy specimens should not be used as a first-line diagnostic tool.

• #21 Gaucher Disease (GD) | Takeda U.S. Medical

  https://www.takedamedconnect.com/diseases-and-conditions/rare-metabolic/gaucher-disease

  However, a definitive diagnosis requires enzymatic analysis of glucocerebrosidase and can also be supplemented by detection of genetic defects. […] Type 2 GD, with substantial CNS involvement, is typically diagnosed in infancy, with bulbar signs and oculomotor paresis, while Type 3 GD is typically diagnosed in childhood or adolescence, often with a progression of CNS involvement. […] Traditional biomarkers (chitotriosidase and CCL18) have demonstrated low sensitivity and lack specificity. […] Glucosylsphingosine (Lyso-Gb1) has been associated with 100% sensitivity/specificity, is correlated with liver volume and bone marrow fat fraction, and with severity of variants in the GBA gene.

• #22 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Gauchers-Disease-Diagnosis.aspx

  Diagnosis is usually made based on a combination of physical assessment and laboratory testing. The blood is tested to check the level of glucocerebrosidase and genetic testing can be used to confirm the diagnosis. Individuals planning a family may want to undergo genetic screening if there is a genetic risk factor such as Ashkenazi Jewish heritage or a family history of the condition. […] Other lysosomal enzymes may also be elevated including tartrate-resistant acid phosphatase, human chitinase, hexosaminidase and chitotriosidase. Chitotriosidase is also useful for monitoring a patients response to enzyme replacement therapy in Gauchers disease. […] Gauchers disease may also be suspected if cytology studies show the cytoplasm resembles the appearance of crinkled paper and has macrophages laden with glycolipid.

• #23 Gaucher’s disease – Wikipedia

  https://en.wikipedia.org/wiki/Gaucher%27s_disease

  Gaucher disease is suggested based on the overall clinical picture. Initial laboratory testing may include enzyme testing. As a result, lower than 15% of mean normal activity is considered to be diagnostic. Decreased enzyme levels will often be confirmed by genetic testing. Numerous different mutations occur; sequencing of the beta-glucosidase gene is sometimes necessary to confirm the diagnosis. Prenatal diagnosis is available and is useful when a known genetic risk factor is present. […] A diagnosis can also be implied by biochemical abnormalities such as high alkaline phosphatase, angiotensin-converting enzyme, and immunoglobulin levels, or by cell analysis showing „crinkled paper” cytoplasm and glycolipid-laden macrophages. […] Some lysosomal enzymes are elevated, including tartrate-resistant acid phosphatase, hexosaminidase, and a human chitinase, chitotriosidase. This latter enzyme has proved to be very useful for monitoring Gaucher’s disease activity in response to treatment and may reflect the severity of the disease.

• #24 Gaucher Disease Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/944157-workup

  Angiotensin-converting enzyme levels typically are elevated, as are total acid phosphatase and ferritin levels. […] In recent years levels of glucosylsphingosine, a downstream metabolic product of glucosylceramide, have been shown to be a useful disease biomarker, as it correlates with disease severity and with response to therapy. […] Bone marrow aspiration should not be the initial diagnostic test because the blood enzyme test is sensitive, specific, and much less invasive; in fact, such biopsies rarely are indicated. […] Liver biopsy occasionally is performed to assess unexplained hepatomegaly. However, it should be avoided in most patients when the diagnosis is suspected because a specific diagnostic test is available. […] In Gaucher disease, classic glycolipid-laden macrophages are found in bone marrow aspirate or in liver biopsy samples. […] Histologic evaluation of biopsy specimens should not be used as a first-line diagnostic tool.

• #25 Gaucher Disease Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/944157-workup

  Diagnosis can be confirmed through measurement of glucocerebrosidase activity in peripheral blood leukocytes. A finding of less than 15% of mean normal activity is diagnostic. […] Molecular diagnosis can be helpful, especially in Ashkenazi patients, in whom 6 GBA1 mutations (ie, N370S, c.84insG, L444P, IVS2+1ga, V394L, and R496H) account for around 90% of disease alleles. However, these variants only account for 50-75% in other ethnicities, and therefore sequencing of the exons of GBA1 is necessary in order to accurately establish the genotype. […] A CBC count with a platelet count and differential should be performed to assess the degree of cytopenia. […] Minor elevations of liver enzyme levels are common, even in patients who are mildly affected with Gaucher disease; however, the presence of jaundice or impaired hepatocellular synthetic function merits a full hepatic evaluation.

• #26 Gaucher disease – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/gauchers-disease/diagnosis-treatment/drc-20355551

  During a physical exam, your doctor will press on your or your child’s abdomen to check the size of the spleen and liver. To determine if your child has Gaucher disease, the doctor will compare your child’s height and weight to standardized growth charts. […] He or she might also recommend certain lab tests, imaging scans and genetic counseling. […] Blood samples can be checked for levels of the enzyme associated with Gaucher disease. Genetic analysis can reveal whether you have the disease. […] People diagnosed with Gaucher disease typically require periodic tests to track its progression, including: […] You might want to consider genetic screening before starting a family if you or your partner is of Ashkenazi Jewish heritage or if either of you have a family history of Gaucher disease. In some cases, doctors recommend prenatal testing to see if the fetus is at risk of Gaucher disease.

• #27 Gaucher Disease Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/944157-workup

  Diagnosis can be confirmed through measurement of glucocerebrosidase activity in peripheral blood leukocytes. A finding of less than 15% of mean normal activity is diagnostic. […] Molecular diagnosis can be helpful, especially in Ashkenazi patients, in whom 6 GBA1 mutations (ie, N370S, c.84insG, L444P, IVS2+1ga, V394L, and R496H) account for around 90% of disease alleles. However, these variants only account for 50-75% in other ethnicities, and therefore sequencing of the exons of GBA1 is necessary in order to accurately establish the genotype. […] A CBC count with a platelet count and differential should be performed to assess the degree of cytopenia. […] Minor elevations of liver enzyme levels are common, even in patients who are mildly affected with Gaucher disease; however, the presence of jaundice or impaired hepatocellular synthetic function merits a full hepatic evaluation.

• #28 Gaucher Disease Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/944157-workup

  Angiotensin-converting enzyme levels typically are elevated, as are total acid phosphatase and ferritin levels. […] In recent years levels of glucosylsphingosine, a downstream metabolic product of glucosylceramide, have been shown to be a useful disease biomarker, as it correlates with disease severity and with response to therapy. […] Bone marrow aspiration should not be the initial diagnostic test because the blood enzyme test is sensitive, specific, and much less invasive; in fact, such biopsies rarely are indicated. […] Liver biopsy occasionally is performed to assess unexplained hepatomegaly. However, it should be avoided in most patients when the diagnosis is suspected because a specific diagnostic test is available. […] In Gaucher disease, classic glycolipid-laden macrophages are found in bone marrow aspirate or in liver biopsy samples. […] Histologic evaluation of biopsy specimens should not be used as a first-line diagnostic tool.

• #29 Gaucher Disease Testing | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/testing/

  Physicians diagnose Gaucher disease (pronounced go-SHAY) with a standard blood test called a beta-glucosidase leukocyte (BGL) test available through major laboratories, i.e. Counsyl, Labcorp or Quest Diagnostics, as well as a hospital or doctors office. […] Doctors use a standard blood test called a beta-glucosidase leukocyte (BGL) test to check enzyme activity and diagnose Gaucher disease. […] Fortunately, bone marrow testing is not necessary to diagnose Gaucher disease. In fact, physicians can diagnose Gaucher disease with an enzyme test available at a hospital or your doctors office. […] An enzyme test called a beta-glucosidase leukocyte (BGL) test is the main tool that physicians use to diagnose Gaucher disease. This is because all patients with Gaucher disease will have low enzyme activity levels.

• #30 Gaucher Disease Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/944157-workup

  Angiotensin-converting enzyme levels typically are elevated, as are total acid phosphatase and ferritin levels. […] In recent years levels of glucosylsphingosine, a downstream metabolic product of glucosylceramide, have been shown to be a useful disease biomarker, as it correlates with disease severity and with response to therapy. […] Bone marrow aspiration should not be the initial diagnostic test because the blood enzyme test is sensitive, specific, and much less invasive; in fact, such biopsies rarely are indicated. […] Liver biopsy occasionally is performed to assess unexplained hepatomegaly. However, it should be avoided in most patients when the diagnosis is suspected because a specific diagnostic test is available. […] In Gaucher disease, classic glycolipid-laden macrophages are found in bone marrow aspirate or in liver biopsy samples. […] Histologic evaluation of biopsy specimens should not be used as a first-line diagnostic tool.

• #31 Gaucher’s disease: Cytochemical diagnosis

  http://imagebank.hematology.org/image/63488/gauchers-disease-cytochemical-diagnosis

  Gaucher’s disease is one of the most common lysosomal storage disorder that occurs due to mutations in the gene encoding glucocerebrosidase. The diagnosis is generally made by cytomorphologic examination of the bone marrow and confirmed by measurement of glucocerebrosidase activity in peripheral blood leucocytes or cultured skin fibroblasts. Histiocytes with diffuse iron uptake should be considered as highly suspicious for Gaucher’s disease, and an appropriate clinical work-up should be instituted.

• #32 Gaucher Disease Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/944157-workup

  Angiotensin-converting enzyme levels typically are elevated, as are total acid phosphatase and ferritin levels. […] In recent years levels of glucosylsphingosine, a downstream metabolic product of glucosylceramide, have been shown to be a useful disease biomarker, as it correlates with disease severity and with response to therapy. […] Bone marrow aspiration should not be the initial diagnostic test because the blood enzyme test is sensitive, specific, and much less invasive; in fact, such biopsies rarely are indicated. […] Liver biopsy occasionally is performed to assess unexplained hepatomegaly. However, it should be avoided in most patients when the diagnosis is suspected because a specific diagnostic test is available. […] In Gaucher disease, classic glycolipid-laden macrophages are found in bone marrow aspirate or in liver biopsy samples. […] Histologic evaluation of biopsy specimens should not be used as a first-line diagnostic tool.

• #33 Diagnosis and Testing Overview | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/diagnosis-testing

  Laboratory testing for Gaucher disease (GD) should be carried out when a patient presents with signs indicative of the disease, such as unexplained splenomegaly, anemia, or thrombocytopenia.15 Suspicion should be higher when the patient is of Ashkenazi Jewish descent.14,15 If GD is suspected, an enzyme assay as well as genetic testing should be performed to confirm the diagnosis. Learn more about the definitive tests for GD1 here. […] A diagnosis of type 1 Gaucher disease (GD1) should be confirmed with an enzyme assay to determine levels of -glucosidase enzyme activity, and genetic testing to identify mutations that cause the disease.1 […] Some states (including Missouri, New York, Illinois, and Tennessee) currently offer genetic testing to screen newborns for Gaucher disease (GD), with further states currently considering implementation of this testing.4 Check the current status of newborn screening for GD in your state in case your patients have questions or need guidance in this area.

• #34 Prenatal Diagnosis of Gaucher Disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4920929/

  Gaucher disease (GD) is a rare disease but is the commonest enzyme deficiency disorder among the group of inherited lysosomal storage diseases. Following genetic counselling and informed consent, direct enzymatic assay of acid beta-glucosidase on chorionic villi samples (CVS) can be offered to families in which GD has been diagnosed. […] Diagnosis of GD is based on assay of glucocerebrosidase activity in peripheral blood leucocytes or cultured fibroblast. Normally GD patients have enzyme activity that is significantly lower than normal (less than 30%). […] Prenatal diagnosis for GD is now available at many centres. Parents should be counselled about the 25% risk of recurrence and the availability of prenatal diagnosis by enzymatic assay in CVS at 10-12 weeks of gestation or amniotic cell culture at 15-18 weeks. […] The couple should be informed about this during counselling for prenatal diagnosis. Aim of this case report is to apprise health care providers about the availability of prenatal diagnosis for GD in our country.

• #35 Gaucher | Baby’s First Test | Newborn Screening | Baby Health

  https://www.babysfirsttest.org/newborn-screening/conditions/gaucher

  Follow-up testing will involve checking your babys blood for signs of Gaucher. When a child has a lysosomal storage disorder, certain substances may be present in reduced amounts. Low levels of the enzyme, beta-glucocerebrosidase, might indicate that your baby has Gaucher. Your babys doctor may want to confirm the diagnosis through clinical genetic testing.

• #36 Diagnosis and Testing Overview | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/diagnosis-testing

  The -glucosidase enzyme assay measures the levels of the enzyme glucocerebrosidase.5 A GD diagnosis is confirmed by establishing glucocerebrosidase enzyme activity in mononuclear cells, leukocytes, or cultured fibroblasts. These are obtained by either a skin biopsy or dried blood spot test.68 Low levels of this enzyme, less than 15% of mean normal activity, indicate a diagnosis of GD.6,9 Enzyme activity, however, does not predict disease severity.1,6 […] Genetic testing requires either a blood or saliva sample, used to extract the patients DNA.10 Genetic sequencing can then be used to detect specific mutations in the GBA1 gene that result in GD.11,12 […] Due to the rare nature and heterogeneous presentation of GD1, patients often consult several different specialists before reaching the correct diagnosis.16,17 Although clinical presentation of variable severity occurs in childhood for the majority of patients, diagnosis is often delayed 1015 years until patients are in adulthood.15,17 Patients are often misdiagnosed, which can lead to disease complications, persistence of untreated symptoms, emotional distress, and frustration and depression at the lack of an explanation for their symptoms.6

• #37 Diagnosis and Testing Overview | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/diagnosis-testing

  The -glucosidase enzyme assay measures the levels of the enzyme glucocerebrosidase.5 A GD diagnosis is confirmed by establishing glucocerebrosidase enzyme activity in mononuclear cells, leukocytes, or cultured fibroblasts. These are obtained by either a skin biopsy or dried blood spot test.68 Low levels of this enzyme, less than 15% of mean normal activity, indicate a diagnosis of GD.6,9 Enzyme activity, however, does not predict disease severity.1,6 […] Genetic testing requires either a blood or saliva sample, used to extract the patients DNA.10 Genetic sequencing can then be used to detect specific mutations in the GBA1 gene that result in GD.11,12 […] Due to the rare nature and heterogeneous presentation of GD1, patients often consult several different specialists before reaching the correct diagnosis.16,17 Although clinical presentation of variable severity occurs in childhood for the majority of patients, diagnosis is often delayed 1015 years until patients are in adulthood.15,17 Patients are often misdiagnosed, which can lead to disease complications, persistence of untreated symptoms, emotional distress, and frustration and depression at the lack of an explanation for their symptoms.6

• #38 Finding and Treating Gaucher Disease Type 1 – The Role of the Haematologist | touchONCOLOGY

  https://touchoncology.com/haematology/journal-articles/finding-and-treating-gaucher-disease-type-1-the-role-of-the-haematologist/

  Diagnosis is often delayed in patients with Gaucher disease type 1. […] A definitive diagnosis of GD can be obtained by measuring -glucosidase activity in peripheral blood leucocytes. […] To accelerate the diagnostic process, two cost-effective, non-invasive DBS assays have been developed for screening -glucosidase activity. […] Algorithms for the diagnosis of Gaucher disease type 1 suggest that -glucosidase activity should be routinely assessed in all high-risk individuals with thrombocytopenia and splenomegaly. […] A survey of 16 medical experts from 14 GD specialist centres across 12 countries found that the main causes of diagnostic delay in patients with GD are a lack of awareness of GD/misdiagnosis, followed by phenotypic heterogeneity/non-specific symptoms, mild symptomatology and outsourced testing. […] Studies conducted in adults across Italy suggest that the use of simple diagnostic algorithms and newly-available DBS assays facilitate the diagnosis of GD and avoid unnecessary biopsies, even among physicians without disease-specific expertise.

• #39 Diagnosis and Testing Overview | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/diagnosis-testing

  One of the key reasons for misdiagnoses is that GD1 symptoms can overlap with a number of other disorders, such as: […] Additional diagnostic challenges of GD1, which may lead to delayed diagnoses or misdiagnoses, include: […] Genetic testing can also be used to identify carriers of GD1. Although carriers do not experience symptoms of the disease, it is important that they are identified because GD is a hereditary condition.12 […] Carrier screening for mutations commonly associated with GD1 is recommended for the Ashkenazi Jewish population and other individuals who are at high risk for the disease.6,20 […] Prompt diagnosis of GD1 is essential because the disease is progressive.5 Delayed recognition and subsequent delayed diagnosis of the disease lead to late management, which can lead to irreversible complications, such as avascular necrosis or multiple myeloma.8,15 Therefore, the aim should be to recognize, diagnose, and treat before the development of such irreversible complications.2 Early recognition can reduce unnecessary investigations and the time to diagnosis, and therefore lead to more effective management strategies and the timely initiation of appropriate treatment.5,16 This can help to alleviate some of the anxiety experienced by patients and their families, and is therefore critical to ensuring the best patient outcomes.16 Regular Monitoring and Management are required for patients with GD1 following their diagnosis.7,8

• #40 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Gaucher disease (GD) is a rare lysosomal storage disorder resulting from a deficiency of the lysosomal enzyme glucocerebrosidase caused by biallelic variants in the GBA1 gene. […] However, many patients with GD experience a lengthy diagnostic odyssey, which can negatively affect their access to care and clinical outcomes. […] This heterogeneity, combined with the molecular complexity of the GBA1 locus, low disease prevalence, and limited knowledge of GD among providers serves as a barrier to early diagnosis of GD. […] Due to the heterogenous nature of the disorder, relatively low prevalence, variation of presentation, and low provider familiarity, patients may experience lengthy diagnostic delays as well as extraneous testing and procedures. […] Earlier diagnosis is essential for improving patient outcomes.

• #41 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Currently, the use of sequencing to identify GBA1 variants, coupled with evaluation of GCase activity, remains the diagnostic gold standard. […] However, technical intricacies in sequencing and measuring enzymatic activity can make diagnosis difficult. […] The use of selected panels can miss up to 15-20% of pathogenic variants. […] Despite multiple decades of study, the gene regulation, expression, and structure at the GBA1/GBAP1 locus remains poorly understood, especially within different cell types. […] The patients initial workup may be non-specific and include anemia, thrombocytopenia, hepatosplenomegaly, or lymphadenopathy, leading to an unclear clinical picture and difficult diagnosis. […] Patients are often misdiagnosed or referred to multiple different specialists, most often hematologist-oncologists, before receiving a diagnosis.

• #42 Obstacles to Early Diagnosis of Gaucher Disease | TCRM

  https://www.dovepress.com/obstacles-to-early-diagnosis-of-gaucher-disease-peer-reviewed-fulltext-article-TCRM

  Among hematologists, there remains a lack of awareness of GD, as a study across seven countries found that only 20% of 406 surveyed hematologist oncologists initially considered GD in a patient presenting with common GD manifestations such as anemia, thrombocytopenia, hepatomegaly, splenomegaly, and bone pain. […] Most diagnostic guidelines recommend genetic testing confirmed with enzyme activity assays. […] However, the clinical utility of available biomarkers, optimal dosing, and criteria for initiation of treatment are still debated. […] Clearer management guidelines and disease surveillance throughout the entire spectrum of GD would help to better quantify the benefits of early treatment initiation, particularly in patients who show few disease manifestations. […] The benefits of adding GD to the RUSP and state-specific newborn screening programs have been debated given unclear genotype/phenotype correlation, variable age of symptom onset, unreliable biomarkers, and the lack of effective treatment for its neuronopathic manifestations. […] Thus, GD remains a nuanced addition to nationwide screening guidelines.

• #43 Diagnosis and Testing Overview | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/diagnosis-testing

  One of the key reasons for misdiagnoses is that GD1 symptoms can overlap with a number of other disorders, such as: […] Additional diagnostic challenges of GD1, which may lead to delayed diagnoses or misdiagnoses, include: […] Genetic testing can also be used to identify carriers of GD1. Although carriers do not experience symptoms of the disease, it is important that they are identified because GD is a hereditary condition.12 […] Carrier screening for mutations commonly associated with GD1 is recommended for the Ashkenazi Jewish population and other individuals who are at high risk for the disease.6,20 […] Prompt diagnosis of GD1 is essential because the disease is progressive.5 Delayed recognition and subsequent delayed diagnosis of the disease lead to late management, which can lead to irreversible complications, such as avascular necrosis or multiple myeloma.8,15 Therefore, the aim should be to recognize, diagnose, and treat before the development of such irreversible complications.2 Early recognition can reduce unnecessary investigations and the time to diagnosis, and therefore lead to more effective management strategies and the timely initiation of appropriate treatment.5,16 This can help to alleviate some of the anxiety experienced by patients and their families, and is therefore critical to ensuring the best patient outcomes.16 Regular Monitoring and Management are required for patients with GD1 following their diagnosis.7,8

• #44 Diagnosis and Testing Overview | Know Gaucher Disease

  https://www.knowgaucherdisease.com/hcp/diagnosis-testing

  One of the key reasons for misdiagnoses is that GD1 symptoms can overlap with a number of other disorders, such as: […] Additional diagnostic challenges of GD1, which may lead to delayed diagnoses or misdiagnoses, include: […] Genetic testing can also be used to identify carriers of GD1. Although carriers do not experience symptoms of the disease, it is important that they are identified because GD is a hereditary condition.12 […] Carrier screening for mutations commonly associated with GD1 is recommended for the Ashkenazi Jewish population and other individuals who are at high risk for the disease.6,20 […] Prompt diagnosis of GD1 is essential because the disease is progressive.5 Delayed recognition and subsequent delayed diagnosis of the disease lead to late management, which can lead to irreversible complications, such as avascular necrosis or multiple myeloma.8,15 Therefore, the aim should be to recognize, diagnose, and treat before the development of such irreversible complications.2 Early recognition can reduce unnecessary investigations and the time to diagnosis, and therefore lead to more effective management strategies and the timely initiation of appropriate treatment.5,16 This can help to alleviate some of the anxiety experienced by patients and their families, and is therefore critical to ensuring the best patient outcomes.16 Regular Monitoring and Management are required for patients with GD1 following their diagnosis.7,8

• #45 Gaucher Disease: Diagnosis and Awareness | CheckRare

  https://checkrare.com/gaucher-disease-diagnosis-and-awareness/

  There are three types of GD. Type 1 Gaucher disease (GD1) is the most prevalent form of the disease, accounting for more than 90% of all cases. […] Early recognition, diagnosis, and treatment of GD1 are key for the best possible patient outcomes and quality of life. […] An early clinical presentation predicts a more severe disease course, highlighting the importance of recognizing GD1 as soon as possible to help ensure earlier intervention and inform treatment decisions.

• #46 Finding and Treating Gaucher Disease Type 1 – The Role of the Haematologist | touchONCOLOGY

  https://touchoncology.com/haematology/journal-articles/finding-and-treating-gaucher-disease-type-1-the-role-of-the-haematologist/

  Diagnosis is often delayed in patients with Gaucher disease type 1. […] A definitive diagnosis of GD can be obtained by measuring -glucosidase activity in peripheral blood leucocytes. […] To accelerate the diagnostic process, two cost-effective, non-invasive DBS assays have been developed for screening -glucosidase activity. […] Algorithms for the diagnosis of Gaucher disease type 1 suggest that -glucosidase activity should be routinely assessed in all high-risk individuals with thrombocytopenia and splenomegaly. […] A survey of 16 medical experts from 14 GD specialist centres across 12 countries found that the main causes of diagnostic delay in patients with GD are a lack of awareness of GD/misdiagnosis, followed by phenotypic heterogeneity/non-specific symptoms, mild symptomatology and outsourced testing. […] Studies conducted in adults across Italy suggest that the use of simple diagnostic algorithms and newly-available DBS assays facilitate the diagnosis of GD and avoid unnecessary biopsies, even among physicians without disease-specific expertise.

• #47 Finding and Treating Gaucher Disease Type 1 – The Role of the Haematologist | touchONCOLOGY

  https://touchoncology.com/haematology/journal-articles/finding-and-treating-gaucher-disease-type-1-the-role-of-the-haematologist/

  Diagnosis is often delayed in patients with Gaucher disease type 1. […] A definitive diagnosis of GD can be obtained by measuring -glucosidase activity in peripheral blood leucocytes. […] To accelerate the diagnostic process, two cost-effective, non-invasive DBS assays have been developed for screening -glucosidase activity. […] Algorithms for the diagnosis of Gaucher disease type 1 suggest that -glucosidase activity should be routinely assessed in all high-risk individuals with thrombocytopenia and splenomegaly. […] A survey of 16 medical experts from 14 GD specialist centres across 12 countries found that the main causes of diagnostic delay in patients with GD are a lack of awareness of GD/misdiagnosis, followed by phenotypic heterogeneity/non-specific symptoms, mild symptomatology and outsourced testing. […] Studies conducted in adults across Italy suggest that the use of simple diagnostic algorithms and newly-available DBS assays facilitate the diagnosis of GD and avoid unnecessary biopsies, even among physicians without disease-specific expertise.

• #48 Finding and Treating Gaucher Disease Type 1 – The Role of the Haematologist | touchONCOLOGY

  https://touchoncology.com/haematology/journal-articles/finding-and-treating-gaucher-disease-type-1-the-role-of-the-haematologist/

  Diagnosis is often delayed in patients with Gaucher disease type 1. […] A definitive diagnosis of GD can be obtained by measuring -glucosidase activity in peripheral blood leucocytes. […] To accelerate the diagnostic process, two cost-effective, non-invasive DBS assays have been developed for screening -glucosidase activity. […] Algorithms for the diagnosis of Gaucher disease type 1 suggest that -glucosidase activity should be routinely assessed in all high-risk individuals with thrombocytopenia and splenomegaly. […] A survey of 16 medical experts from 14 GD specialist centres across 12 countries found that the main causes of diagnostic delay in patients with GD are a lack of awareness of GD/misdiagnosis, followed by phenotypic heterogeneity/non-specific symptoms, mild symptomatology and outsourced testing. […] Studies conducted in adults across Italy suggest that the use of simple diagnostic algorithms and newly-available DBS assays facilitate the diagnosis of GD and avoid unnecessary biopsies, even among physicians without disease-specific expertise.

• #49 Assessing the diagnostic utility of the Gaucher Earlier Diagnosis Consensus (GED-C) scoring system using real-world data | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03042-y

  An enhanced diagnostic model may lead to earlier, reliable diagnoses of Gaucher disease, aiming to minimize the severe complications associated with this disease. […] The Gaucher Earlier Diagnosis Consensus (GED-C) scoring system was developed by a panel of 22 expert physicians using Delphi methodology regarding the signs and covariables considered important for diagnosing type 1 and type 3 GD, to help clinicians identify potential individuals to test further, thereby reducing diagnostic delay. […] The ability of the GED-C to discriminate between individuals with and without GD was also shown by other groups. […] The GED-C score, developed by Delphi expert consensus, shows good discrimination between patients with GD and controls and could be the basis for future models. […] The application of machine learning techniques to our cohort is expected to result in an improved diagnostic model with the best possible sensitivity that may be used for screening undiagnosed GD cases.

• #50

  https://www.indianpediatrics.net/feb2018/feb-143-153.htm

  Justification: Gaucher disease (GD) is amongst the most frequently occurring lysosomal storage disorder in all ethnicities. […] Recommendations: Manifestations of GD are protean and a high index of suspicion is essential for timely diagnosis. Patients frequently experience diagnostic delays during which severe irreversible complications occur. Leucocyte acid b-glucosidase activity is mandatory for establishing the diagnosis of Gaucher disease; molecular testing can help identify patients at risk of neuronopathic disease. […] We herein provide guidelines and recommendations for an optimal approach to diagnosis and management of Gaucher disease in Indian patients. […] The gold standard for diagnosis of Gaucher disease is acid b-glucocerebrosidase enzyme assay in blood leucocytes; Gaucher disease patients have levels 10% of controls.

• #51

  https://www.indianpediatrics.net/feb2018/feb-143-153.htm

  Molecular diagnosis: Molecular testing and identification of the GBA mutation confirms the diagnosis and in addition the genotype information aids prognostication, carrier-testing and prenatal diagnosis. […] Bone marrow biopsy is not essential for diagnosis and the absence of Gaucher cells in the bone marrow does not exclude the diagnosis of Gaucher disease. […] Chitotriosidase is a useful biomarker for serial monitoring of individual patients receiving ERT; it should be used in the context of other clinical indicators of disease activity.

• #52

  https://journals.lww.com/jaht/fulltext/2021/12030/diagnosis_and_management_of_hematological.1.aspx

  The experts recommended the following to support diagnosis: Educating primary care physicians to include GD in their differential diagnosis when encountering thrombocytopenia, anemia and splenomegaly will help to reduce the diagnostic delay, especially in the remote areas of Saudi Arabia. […] The experts’ assent to that the general physicians, but not hematologists, are the ones who need further education on GD. […] The experts recommended the use of standard cut-off values for different diagnostic parameters. […] If the bone marrow biopsy showed Gaucher cells, an exclusion of conditions that are associated with pseudo-Gaucher cells should be done before the establishment of the GD diagnosis. […] The intense efforts from different societies in the Saudi Arabia to create a unified algorithm for GD diagnosis will undoubtedly facilitate the diagnosis, especially for nonhematologists.

• #53 Symptoms of Gaucher Disease | Cerezyme® (imiglucerase)

  https://www.cerezyme.com/hcp/treating-gaucher-disease/symptoms

  It takes only 1 simple blood test to make a diagnosis if you suspect Gaucher disease. […] Glucosidase enzyme assay is the standard, recommended method for establishing a confirmatory diagnosis of Gaucher disease, which is demonstrated by deficiency of -glucosidase activity. […] Molecular testing (DNA) can be used to confirm the type of Gaucher disease as well as carrier status. […] Don’t miss a Gaucher disease diagnosis. Test to know. It’s just a simple blood-based enzyme assay (-glucosidase).

• #54 Gaucher Disease Testing | National Gaucher Foundation

  https://www.gaucherdisease.org/gaucher-diagnosis-treatment/testing/

  A beta-glucosidase leukocyte (BGL) test will almost certainly show whether or not a person has Gaucher disease since all patients with the disease have low enzyme activity. […] For carrier testing, a targeted mutation test will identify roughly 89 percent of carriers. Gene sequencing can identify over 99 percent of Gaucher disease carriers. […] You should get tested if you experience symptoms of Gaucher disease, or if it runs in your family. […] A bone marrow test is not required to diagnose Gaucher disease. However, some doctors end up diagnosing Gaucher disease with this test while trying to rule out other blood disorders.

Zobacz więcej